JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells
Kaya, Tijen Temiz; Altun, Ahmet; Turgut, Nergiz Hacer; Ataseven, Hilmi; Koyluoglu, Gokhan;
  PDF(new window)
 Abstract
In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29). Real time cell analysis (RTCA, Xcelligence system) was used to determine the effects on colorectal cancer cell proliferation. Apoptosis was assessed with annexin V staining and angiogenesis was determined with chorioallantoic membrane model. We found that motesanib alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Combination with DUP-697 increased the antiproliferative, antiangiogenic and apoptotic effects. Results of this study indicate that motesanib may be a good choice in treatment of colorectal tumors. In addition, the increased effects of combination of motesanib with DuP-697 raise the possibility of using lower doses of these drugs and therefore avoid/minimize the dose-dependent side effects generally observed.
 Keywords
Colorectal cancer;motesanib;multikinase inhibitor;COX-2 inhibition;
 Language
English
 Cited by
 References
1.
Agarwal V, Hodgkinson VC, Eagle GL, et al (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol, 42, 1088-92.

2.
Altun A, Turgut NH, Kaya TT (2014).Anticancer effect of COX-2 inhibitor DuP-697 alone and in combination with tyrosine kinase inhibitor (E7080) on colon cancer cell lines. Asian Pac J Cancer Prev, 15, 3113-21. crossref(new window)

3.
Bestas R, Kaplan MA, Isikdogan A (2014). The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. Hepatogastroenterol, 61, 267-71.

4.
Agarwal V, Hodgkinson VC, Eagle GL, et al (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. Int J Oncol, 42, 1088-92.

5.
Blumenschein GR Jr, Kabbinavar F, Menon H, et al (2011). Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol, 22, 2057-67. crossref(new window)

6.
Burgermeister J, Paper DH, Vogl H, et al. (2002) LAPSvS1, a ($1{\rightarrow}3$)-betagalactan sulfate and its effect on angiogenesis in vitro andin vivo. Carbohydr Res, 337, 1459-66. crossref(new window)

7.
Cathcart MC, O’Byrne KJ, Reynolds JV, O’Sullivan J, Pidgeon GP (2012). COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta, 1825, 49-63.

8.
Center M.M, Jemal A, Ward E (2009). International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev, 18, 1688-94. crossref(new window)

9.
Chu E (2012). An update on the current and emerging targeted agents in metastatic colorectal. Cancer, 11, 1-13.

10.
Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT (2003). Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther, 2, 1-7.

11.
Coxon A, Bush T, Saffran D, et al (2009). Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res, 15, 110-8. crossref(new window)

12.
Coxon A, Ziegler B, Kaufman S, et al (2012) a. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer, 11, 70. crossref(new window)

13.
Coxon A, Bready J, Kaufman S, et al (2012) b. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest, 35, 181-90.

14.
Cui Y, Deming-Halverson SL, Shrubsole MJ, et al (2014). Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat, 146, 439-46 crossref(new window)

15.
De Boer RH, Kotasek D, White S, et al (2012). Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat, 135, 241-52. crossref(new window)

16.
Demirci B, Dadandi MY, Paper DH, et al (2003). Chemical composition of the essential oil of Phlomis linearis Boiss.&Bal., and biologicaleffects on the CAM assay: a safety evaluation. Z Naturforsch C, 58, 826-9.

17.
Hohla F, Winder T, Greil R, et al 2014. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World J Gastroenterol, 20, 6102-12. crossref(new window)

18.
Kim BH, Kim CI, Chang HS, et al (2011). Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean J Urol, 52, 253-9. crossref(new window)

19.
Kim JY, Chung SW, Kim SY, Byun Y (2015). Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor. Pharm Res, 32, 2318-27. crossref(new window)

20.
Li M, Tan SY, Wang XF (2014). Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of $PGE{\geq}$ synthesis and COX-2 expression. Oncol Rep, 32, 2845-53.

21.
Lu JF, Claret L, Sutjandra L et al (2010).Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol, 66, 1151-8 crossref(new window)

22.
Ma L, del Soldato P, Wallace JL (2002). Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A. 99, 13243-7. crossref(new window)

23.
Ninomiya I, Nagai N, Oyama K, et al (2012). Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep, 28, 777-84.

24.
Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M (2007). Cyclooxygenase-2 expression correlates with apoptosis and angiogenesis in endometrial cancer tissue. Anticancer Res, 27, 3765-70.

25.
Paudyal B, Paudyal P, Shah D, et al (2014). Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate. J Biomed Sci, 21, 35. crossref(new window)

26.
Roche Diagnostics GmbH (2008). Introduction of the RTCA SPInstrument. RTCA SP Instrument Operator's Manual, A. Acea Biosciences, 2008, 14-6.

27.
Qiu ZQ, Qiu ZR (2015). Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression. Asian Pac J Cancer Prev, 16, 3447-50. crossref(new window)

28.
Peng HL, Zhang GS, Liu JH, Gong FJ, Li RJ (2008).Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol, 87, 121-9. crossref(new window)

29.
Riaz SK, Iqbal Y, Malik MF (2015). Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer. Asian Pac J Cancer Prev, 16, 1677-82. crossref(new window)

30.
Rosen LS, Kurzrock R, Mulay M, et al (2007). Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol, 25, 2369-76. crossref(new window)

31.
Saleem TH, Attya AM, Ahmed EA, et al (2015). Possible Protective Effects of Quercetin and Sodium Gluconate Against Colon Cancer Induction by Dimethylhydrazine in Mice. Asian Pac J Cancer Prev, 16, 5823-8. crossref(new window)

32.
Salimi M, Esfahani M, Habibzadeh N, et al (2012). Change in nicotine-induced VEGF, PGE2 AND COX-2 expression following COX inhibition in human oral squamous cancer. J Environ Pathol Toxicol Oncol, 31, 349-56. crossref(new window)

33.
Salinas CA, Kwon EM, FitzGerald LM, et al (2010). Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol, 172, 578-90. crossref(new window)

34.
Saraiva AL, Payan-Carreira R, Gartner F, et al (2015). Immunohistochemical expression of cyclooxygenase-2 (COX-2) in feline endometrial adenocarcinoma and in normal and hyperplastic endometria. Reprod Domest Anim, 50, 333-40. crossref(new window)

35.
Schilder RJ, Sill MW, Lankes HA, et al (2013). A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol, 129, 86-91. crossref(new window)

36.
Steinbach G, Lynch PM, Phillips RK, et al (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342, 1946-52. crossref(new window)

37.
Shimizu K, Yukawa T, Okita R, et al (2015). Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol, 13, 21. crossref(new window)

38.
Tan HK, Moad AI, Tan ML (2014). The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac J Cancer Prev, 15, 6463-75. crossref(new window)

39.
Tebbutt N, Kotasek D, Burris HA, et al (2015). Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol, 75, 993-1004. crossref(new window)

40.
Tu B, Ma TT, Peng XQ, et al (2014). Targeting of COX-2 expression by recombinant adenovirus shRNA attenuates the malignant biological behavior of breast cancer cells. Asian Pac J Cancer Prev, 15, 8829-36. crossref(new window)

41.
van de Velde CJ, Boelens PG, Tanis PJ, et al (2014). Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur J Surg Oncol, 40, 454-68. crossref(new window)

42.
Wei D, Wang L, He Y, et al (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res, 64, 2030-8. crossref(new window)

43.
Wong VW, Chan FK (2007). Aspirin reduced the incidence of colorectal cancer during 23-year follow-up in healthy men or patients with recent TIA. ACP J Club, 147, 72.

44.
Yazawa K, Tsuno NH, Kitayama J, et al (2005). Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest. Int J Cancer, 113, 541-8. crossref(new window)

45.
Zhu LM, Zhao YZ, Ju HX, et al (2014). Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. Asian Pac J Cancer Prev, 15, 6559-64. crossref(new window)